Health
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC).1,2AbbVie concludes letter of intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI® f
About this update from Abbvie Inc.
[{"type":"image","alt":"AbbVie Canada","displaySize":"","headline":null,"caption":"AbbVie Canada","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/e6a8b96561cb2c1b3eb3c1ee1cf07478"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/i9NcqmrSJq1lWAPOHE3lbg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e6a8b96561cb2c1b3eb3c1ee1cf07478","width":300,"height":92}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC).1,2","length":387,"tagName":"p"}]},{"val":[{"type":"text","content":"AbbVie concludes letter of intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI® for UC.3","length":120,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":507,"olType":false},{"type":"text","content":"MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with ulcerative colitis (UC).","length":156,"tagName":"p"},{"type":"text","content":"Canada’s Drug Agency (CDA-AMC) has recommended SKYRIZI® (risankizumab) to be reimbursed with conditions by public drug plans for the treatment of adults with moderately to severely active UC who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor if certain conditions are met.2","length":377,"tagName":"p"},{"type":"text","content":"The CDA-AMC’s positive recommendation was informed by feedback from 25 Canadian clinicians and two patient organizations, including the GI Society and Crohn’s and Colitis Canada, ensuring that the voices of those living with UC were considered.","length":244,"tagName":"p"},{"type":"text","content":"AbbVie has also successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI® for UC and a Letter of Intent (LOI) has been signed by bo...